-

LENSAR to Participate in Two Upcoming Investor Conferences

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences:

  • H.C. Wainwright 26th Annual Global Investment Conference
    On-demand presentation available Monday, September 9, 2024 at 7:00 a.m. Eastern Time.
  • Lake Street Capital Markets 8th Annual Best Ideas Growth Conference
    Management will conduct one-on-one meetings with institutional investors on September 12, 2024 in New York.

The on-demand H.C. Wainwright presentation will be available beginning at 7:00 a.m. Eastern Time on Monday, September 9, 2024 and can be accessed through the Investors section of the Company's website at https://ir.lensar.com.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its ALLY® Adaptive Cataract Treatment System as a compact, highly ergonomic system utilizing an extremely fast dual-pulse laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons to achieve better outcomes.

Contacts

Thomas R. Staab, II, CFO
ir.contact@lensar.com

Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com

Industry:

LENSAR, Inc.

NASDAQ:LNSR
Release Versions
English

Contacts

Thomas R. Staab, II, CFO
ir.contact@lensar.com

Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com

More News From LENSAR, Inc.

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,425 shares of the Company’s common stock. The options were granted as of September 3, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq...

LENSAR Reports Second Quarter 2024 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR®, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2024 and provided an update on key operational initiatives. “The second quarter was yet another period of solid growth driven by a record number of 17 ALLY® System placements, a substantive increase in our backlog of ALLY Systems pending in...

LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment System (“ALLY” or “ALLY System”) has received certification under the European Union’s (“EU”) Medical Device Regulation (“MDR”). “We are thrilled to receive EU MDR certification for ALLY, which marks a significant milestone for LENSAR. We believe A...
Back to Newsroom